Management of Inadequate Glycemic Control with Alternative Medications

Recommended Treatment Approach

• The American Diabetes Association guidelines recommend adding a GLP-1 receptor agonist when A1C remains ≥1.5% above target, providing superior A1C reduction with additional cardiovascular benefits, weight loss, and minimal hypoglycemia risk 1, 2
• GLP-1 RAs achieve equivalent or superior A1C reduction compared to insulin without the associated weight gain and hypoglycemia risk, and can reduce A1C by 1-2% in patients with A1C of 9.0% on metformin monotherapy 1
• Sulfonylureas added to metformin can reduce A1C by approximately 1-1.5% 3
• The American Diabetes Association suggests that DPP-4 inhibitors, such as sitagliptin, provide a mean A1C reduction of 2.1% from baseline, with a lower hypoglycemia risk compared to sulfonylureas 2, 3

Considerations for Specific Medications

• The American Heart Association and the American Diabetes Association recommend reserving insulin for patients with severe hyperglycemia, symptomatic hyperglycemia, or ketosis, and starting with basal insulin at 10 units or 0.1-0.2 units/kg daily 2, 4
• The American Diabetes Association advises against using thiazolidinediones, such as pioglitazone, in patients with heart failure history due to the risk of fluid retention, heart failure exacerbation, bone fractures, and weight gain 2, 3

Implementation Strategy

• The American Diabetes Association recommends screening for cardiovascular disease, heart failure, and chronic kidney disease before selecting an agent, and prioritizing GLP-1 RAs with proven CV benefit if cardiovascular disease is present 1, 2
• The American Association of Clinical Endocrinologists suggests reassessing A1C in 3 months after treatment intensification 1, 5
• The American Diabetes Association advises monitoring for hypoglycemia symptoms, checking vitamin B12 levels periodically on long-term metformin, and assessing renal function before and during treatment 1, 2, 5

Adding a GLP-1 Receptor Agonist to Existing Therapy

Rationale and Implementation

• Insulin should be reserved for patients with severe hyperglycemia, symptomatic hyperglycemia, or ketosis, according to the American Diabetes Association guidelines, and is not recommended for patients with A1C 8.2% like the one in question 6
• Exclude contraindications to GLP-1 receptor agonists, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as recommended by the American Diabetes Association 7

Monitoring and Follow-up

• Monitor for gastrointestinal side effects, which are common with GLP-1 receptor agonists, especially during dose titration, as reported in Diabetes Care 7

Common Pitfalls to Avoid

• Do not combine GLP-1 receptor agonists with DPP-4 inhibitors in typical practice, though continuing sitagliptin during GLP-1 receptor agonist initiation is acceptable as a transition strategy before discontinuing the DPP-4 inhibitor, as recommended by Diabetes Care 6